Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/29/2026, 12:00:00 AM
Announced in its Q1 2026 report that the FDA approved extending the dosing intervals for EYLEA HD up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Medium importance assigned due to expanded label for a key product, estimated to impact price by ≥5% scheduled.
Korean Translation
2026년 1분기 보고서에서 FDA가 습성 연령 관련 황반변성(wAMD) 및 당뇨병성 황반부종(DME) 환자를 대상으로 아일리아 HD(EYLEA HD)의 투여 간격을 최대 20주까지 연장하는 것을 승인했다고 발표함. 주요 제품의 적응증 확대로 5% 이상의 주가 영향이 예상됨.
Related Recent Events
Bristol-Myers Squibb Co (BMY) · Other
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026, for its decision on iberdomide for relapsed or refractory multiple myeloma, scheduled. Low impact estimated as the target date is a procedural milestone.
8/17/2026, 12:00:00 AM
Blackstone Inc (BX) · Earnings Release
Blackstone is scheduled to release its Q2 2026 earnings results, with analysts forecasting earnings of approximately $1.34-$1.36 per share, scheduled.
7/23/2026, 12:00:00 AM
Union Pacific Corp (UNP) · Earnings Release
Q2 2026 earnings release is scheduled. Low impact estimated as the date announcement is a routine event; scheduled.
7/23/2026, 12:00:00 AM
Goldman Sachs Group Inc (The) (GS) · Earnings Release
Goldman Sachs' Q2 2026 earnings release is scheduled.
7/14/2026, 12:00:00 AM
NIKE Inc (NKE) · Earnings Release
Q4 Fiscal Year 2026 earnings release is scheduled for June 25, 2026. Low importance as the announcement of the date typically has a minimal market impact.
6/25/2026, 12:00:00 AM
Vistra Corp (VST) · Other
Quarterly dividend of $0.2290 per share with an ex-dividend date of June 22, 2026; low importance estimated as dividends usually cause minor price adjustments, scheduled.
6/22/2026, 12:00:00 AM